

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institutes of Mental Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Mental Health Council, May 9, 2002, 10:30 a.m. to May 10, 2002, 2 p.m., National Institutes of Health, Building 1, Wilson Hall, 9000 Rockville Pike, Bethesda, MD, 20892 which was published in the **Federal Register** on April 5, 2002, 67 FR 16413.

The open Policy session day on May 10, 2002, will be held at the National Institutes of Health, 9000 Rockville Pike, Building 31C, Conference Room 6, from 8:30 a.m. until adjournment. The meeting is partially Closed to the public.

Dated: May 9, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-12222 Filed 5-15-02; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; Interventions Research Review.

*Date:* June 4-5, 2002.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Governor's House, 1615 Rhode Island Avenue, NW, Washington, DC 20036.

*Contact Person:* David I. Sommers, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6144, MSC 9606,

Bethesda, MD 20892-9606, 301-443-6470, [dsommers@mail.nih.gov](mailto:dsommers@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: May 9, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-12223 Filed 5-15-02; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, R21 Application Review.

*Date:* May 30, 2002.

*Time:* 2 p.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* 6000 Executive Boulevard, Suite 409, Rockville, MD 20852 (Telephone Conference Call).

*Contact Person:* Eugene G. Hayunga, PhD, Chief, Extramural Project Review Branch, OSA, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Willco Building, Suite 409, 6000 Executive Boulevard, MSC 7003, Bethesda, MD 20892-7003, 301-443-2860, [ehayunga@mail.nih.gov](mailto:ehayunga@mail.nih.gov).

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Initial Review Group, Clinical and Treatment Subcommittee.

*Date:* June 27-28, 2002.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn, 750 Kearny Street, San Francisco Financial District, San Francisco, CA 94108.

*Contact Person:* Elsie Taylor, MS, Scientific Review Administrator, Extramural Project Review Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Suite 409, 6000 Executive Blvd., Bethesda, MD 20892-7003, 301-443-9787, [etaylor@niaaa.nih.gov](mailto:etaylor@niaaa.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: May 9, 2002.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 02-12225 Filed 5-15-02; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Alzheimer's Disease Neuroimaging Initiative

The National Institute on Aging (NIA) is announcing a meeting for the development of a neuroimaging initiative for Alzheimer's disease (AD) that will take place June 17-18, 2002 at the Hyatt Hotel, One Bethesda Metro Center, Bethesda, MD. The goal of this initiative is to foster a public-private collaboration for the development of longitudinal studies that will identify the neuroimaging modalities and techniques most appropriate for following elderly people as they develop mild cognitive impairment (MCI) and AD. In addition to providing natural history information, neuroimaging markers may allow early identification of individuals who may benefit from emerging preventive and treatment medications, provide a way of monitoring treatment efficacy and mechanism, and serve as surrogate endpoints in clinical trials.

Meeting participants will include representatives from academia, the Food and Drug Administration, pharmaceutical companies, imaging device companies, NIH staff, and advocacy groups. Presentations at the meeting will evaluate currently existing resources and knowledge regarding neuroimaging in MCI and AD by examining available clinical, neuropsychological, laboratory, and imaging data from prior natural history and epidemiology studies and clinical